Adoptive Cellular Gene Therapy in Type 1 Diabetes (T1D)

1 型糖尿病 (T1D) 的过继细胞基因疗法

• 批准号: 7110272
• 负责人: CHARLES GARRISON FATHMAN
• 金额: $ 38.08万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-30 至 2007-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7110272
• 关键词: CD3 molecule; NOD mouse; antiantibody; autologous transplantation; biomarker; biotechnology; bone marrow transplantation; dendritic cells; diabetes mellitus therapy; gene therapy; immunotherapy; inflammation; insulin dependent diabetes mellitus; interleukin 4; microarray technology; prediabetic state; transfection; transfection /expression vector

DESCRIPTION (provided by applicant): Published studies from Dr. Fathman's laboratory have demonstrated that murine T cell hybridomas, retrovirally transduced to express immunoregulatory proteins, can halt the induction or progression of disease in several mouse models of autoimmune disease including collagen-induced arthritis (CIA), experimental allergic encephalomyelitis (EAE) and, in more recent unpublished observations, block the progression from recent onset hyperglycemia to overt type 1 diabetes (T1D) in non-obese diabetic (NOD) mice. These recent unexpected findings offer the potential to intervene in human T1D at the stage of recent onset hyperglycemia with a form of "adoptive cellular gene therapy" that may potentially be extended to the prevention of progression from insulitis to hyperglycemia, not only in the NOD mouse, but in "high risk" pre-diabetic human T1D. The technology required to move from islet-antigen-reactive murine T cell hybridomas, as vehicles for "drug delivery," to murine autologous dendritic cells for gene therapy of T1D, is requested as part of this R21 development and feasibility approach to the treatment of recent onset hyperglycemia in T1D. Preliminary data, obtained recently, support the hypothesis that dendritic cells (DCs) are as effective as T cell hybridomas in delivering the therapeutic regulatory protein(s) to the inflammatory lesions of autoimmunity. A second major goal of the proposed R21 studies (that will continue into the R33 funding) is to use cDNA microarray technology to attempt to understand the mechanism(s) of this form of therapy, as well as potentially identify surrogate markers of success or identify additional targets for therapeutic intervention. It is additionally proposed to use herpes simplex virus type 1 thymidine kinase (HSV1-tk) as a marker to follow the trafficking of adoptively transferred DCs in real time in vivo in NOD mice (R21) and to use this knowledge to transfer the imaging technology to man (R33). Finally, under requested R33 support, a Phase I trial of transduction and infusion of autologous DCs into recently hyperglycemic T1D patients for safety studies and to observe cell trafficking is proposed.

描述（由申请人提供）：